164 related articles for article (PubMed ID: 3258793)
1. Effects of phenytoin on cell-mediated immunity.
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Tsuda N; Matsui Y; Mogami H
Cancer Immunol Immunother; 1988; 26(2):176-9. PubMed ID: 3258793
[TBL] [Abstract][Full Text] [Related]
2. [Effects of anticonvulsants on cellular immunity].
Okamoto Y; Shimizu K; Tamura K; Yamada M; Matsui Y; Hayakawa T; Mogami H
No To Shinkei; 1989 Mar; 41(3):299-304. PubMed ID: 2503016
[TBL] [Abstract][Full Text] [Related]
3. [Effects of phenytoin on cell-mediated immunity].
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Mogami H
No To Shinkei; 1987 Oct; 39(10):931-6. PubMed ID: 3501727
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Mulé JJ; Schwarz SL; Roberts AB; Sporn MB; Rosenberg SA
Cancer Immunol Immunother; 1988; 26(2):95-100. PubMed ID: 2452015
[TBL] [Abstract][Full Text] [Related]
5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of cytotoxic T lymphocytes and lymphokine-activated killer cells to inhibition by L-ornithine.
Susskind BM; Sekar J; Tandon PM; Lind DS; Bear HD
Cell Immunol; 1991 Mar; 133(1):41-54. PubMed ID: 1899361
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
9. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.
Aoki T; Kikuchi H; Miyatake S; Oda Y; Iwasaki K; Yamasaki T; Kinashi T; Honjo T
J Exp Med; 1989 Aug; 170(2):583-8. PubMed ID: 2787831
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
13. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
14. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
15. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.
Leshem B; Epstein E; Kedar E
Immunol Lett; 1989 Jan; 20(1):53-8. PubMed ID: 2785493
[TBL] [Abstract][Full Text] [Related]
16. Activated allogeneic NK cells as suppressors of alloreactive responses.
Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression following 7,12-dimethylbenz[a]anthracene exposure in B6C3F1 mice--II. Altered cell-mediated immunity and tumor resistance.
Dean JH; Ward EC; Murray MJ; Lauer LD; House RV; Stillman W; Hamilton TA; Adams DO
Int J Immunopharmacol; 1986; 8(2):189-98. PubMed ID: 3086244
[TBL] [Abstract][Full Text] [Related]
18. Effect of electric foot shock and psychological stress on activities of murine splenic natural killer and lymphokine-activated killer cells, cytotoxic T lymphocytes, natural killer receptors and mRNA transcripts for granzymes and perforin.
Li Q; Liang Z; Nakadai A; Kawada T
Stress; 2005 Jun; 8(2):107-16. PubMed ID: 16019602
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
20. Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.
Ames IH; Gates CE; Garcia AM; John PA; Hennig AK; Tomar RH
Cancer Immunol Immunother; 1987; 25(3):161-8. PubMed ID: 3499983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
